Altercating Leishmaniasis: Cultivating Improved Vaccines

Neha Dhingra¹ and Sandeep Satapathy^2,

¹Department of Zoology, University of Delhi, Delhi, India

²Department of Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India

Cite this paper:
Neha Dhingra and Sandeep Satapathy. Altercating Leishmaniasis: Cultivating Improved Vaccines. American Journal of Infectious Diseases and Microbiology. 2014; 2(1):11-16. doi: 10.12691/ajidm-2-1-3

Abstract

The exponentially rising cases of Leishmaniasis over the past decades, has attracted scientists and clinicians to mitigate the contagious infection by modern treatments and new generation vaccinations. Leishmania, the causative pathogen of this infection predominantly expresses its diseased condition in form of cutaneous leishmaniasis. Although systemic leishmaniasis, is a more deadly form, but cases of its manifestation are limited; thereby staging the focus onto more intricate study of cutaneous leishmaniasis. Designing a vaccine against Leishmania has witnessed more than two generations of vaccine, but each attempt has failed more than it’s cases of success. The proposed drawbacks root to the difficulty in ensuring an efficient transition of research from simple laboratory experiments carried out in-vitro/in-vivo in small animals to that of the humans. There have been extensive case studies of this disease and thus every immunological aspect has been our focus. This paper is an attempt to decipher the ideas and methodologies adopted till date and further target the genetic spans and molecular moieties, for crafting an alternative vaccine based on efforts to mock the pathogenic pathways.

Keywords:
cutaneous proteomics recombinant DNA macrophage life cycle live-attenuated vaccines

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	M. Olivier, D. J. Gregory, and G. Forget, “Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view,” Clinical Microbiology Reviews, vol. 18, no. 2, pp. 293-305, 2005.
[2]	M. E. Reyland, “Protein kinase C isoforms: multi-functional regulators of cell life and death,” Frontiers in Bioscience, vol. 14, pp. 2386-2399, 2009.
[3]	S. Ghosh, S. Bhattacharyya, S. Das et al., “Generation of ceramide in murine macrophages infected with Leishmania donovani alters macrophage signaling events and aids intracellular parasitic survival,” Molecular and Cellular Biochemistry, vol. 223, no. 1-2, pp. 47-60, 2001.
[4]	J. S. Rawlings, K. M. Rosler, and D. A. Harrison, “The JAK/STAT signaling pathway,” Journal of Cell Science, vol. 117, no. 8, pp. 1281-1283, 2004.
[5]	I. Woldman, L. Varinou, K. Ramsauer, B. Rapp, and T. Decker, “The stat1 binding motif of the interferon-γ receptor is sufficient to mediate stat5 activation and its repression by SOCS3,” The Journal of Biological Chemistry, vol. 276, no. 49, pp. 45722-45728, 2001.
[6]	M. Ray, A. A. Gam, R. A. Boykins, and R. T. Kenney, “Inhibition of interferon-γ signaling by Leishmania donovani,” Journal of Infectious Diseases, vol. 181, no. 3, pp. 1121-1128, 2000.
[7]	S. Boldt and W. Kolch, “Targeting MAPK signalling: prometheus' fire or pandora's box?” Current Pharmaceutical Design, vol. 10, no. 16, pp. 1885-1905, 2004.
[8]	C. Privé and A. Descoteaux, “Leishmania donovani promastigotes evade the activation of mitogen-activated protein kinases p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase-1/2 during infection of naive macrophages,” European Journal of Immunology, vol. 30, no. 8, pp. 2235-2244, 2000.
[9]	G. Forget, D. J. Gregory, L. A. Whitcombe, and M. Olivier, “Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production,” Infection and Immunity, vol. 74, no. 11, pp. 6272-6279, 2006.
[10]	S. Ghosh, S. Bhattacharyya, M. Sirkar et al., “Leishmania donovani suppresses activated protein 1 and NF-κB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase,” Infection and Immunity, vol. 70, no. 12, pp. 6828-6838, 2002.
[11]	P. Cameron, A. McGachy, M. Anderson et al., “Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-κB signaling pathway,” The Journal of Immunology, vol. 173, no. 5, pp. 3297-3304, 2004.
[12]	A. Awasthi, R. Mathur, A. Khan et al., “CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response,” Journal of Experimental Medicine, vol. 197, no. 8, pp. 1037-1043, 2003.
[13]	M. Junghae and J. G. Raynes, “Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages,” Infection and Immunity, vol. 70, no. 9, pp. 5026-5035, 2002.
[14]	L. Guizani-Tabbane, K. Ben-Aissa, M. Belghith, A. Sassi, and K. Dellagi, “Leishmania major amastigotes induce p50/c-Rel NF-κB transcription factor in human macrophages: involvement in cytokine synthesis,” Infection and Immunity, vol. 72, no. 5, pp. 2582-2589, 2004.
[15]	D. J. Gregory, M. Godbout, I. Contreras, G. Forget, and M. Olivier, “A novel form of NF-κB is induced by Leishmania infection: involvement in macrophage gene expression,” European Journal of Immunology, vol. 38, no. 4, pp. 1071-1081, 2008.
[16]	G. Forget, D. J. Gregory, and M. Olivier, “Proteasome-mediated degradation of STAT1α following infection of macrophages with Leishmania donovani,” The Journal of Biological Chemistry, vol. 280, no. 34, pp. 30542-30549, 2005.
[17]	J. V. Ravetch and L. L. Lanier, “Immune inhibitory receptors,” Science, vol. 290, no. 5489, pp. 84-89, 2000.
[18]	I. Contreras, M. A. Gómez, O. Nguyen, M. T. Shio, R. W. McMaster, and M. Olivier, “Leishmania-induced inactivation of the macrophage transcription Factor AP-1 Is Mediated by the Parasite Metalloprotease GP63,” PLoS Pathogens, vol. 6, no. 10, Article ID e1001148, 2010.
[19]	M. Larsen, M. L. Tremblay, and K. M. Yamada, “Phosphatases in cell-matrix adhesion and migration,” Nature Reviews Molecular Cell Biology, vol. 4, no. 9, pp. 700-711, 2003.
[20]	L. I. Pao, K. Badour, K. A. Siminovitch, and B. G. Neel, “Nonreceptor protein-tyrosine phosphatases in immune cell signaling,” Annual Review of Immunology, vol. 25, pp. 473-523, 2007.
[21]	M. Elchebly, A. Cheng, and M. L. Tremblay, “Modulation of insulin signaling by protein tyrosine phosphatases,” Journal of Molecular Medicine, vol. 78, no. 9, pp. 473-482, 2000.
[22]	M. P. Myers, J. N. Andersen, A. Cheng et al., “TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B,” The Journal of Biological Chemistry, vol. 276, no. 51, pp. 47771-47774, 2001.
[23]	M. A. Gomez, I. Contreras, M. Hallé, M. L. Tremblay, R. W. McMaster, and M. Olivier, “Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases,” Science Signaling, vol. 2, no. 90, article ra58, 2009.
[24]	P. D. Simoncic, A. Lee-Loy, D. L. Barber, M. L. Tremblay, and C. J. McGlade, “The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3,” Current Biology, vol. 12, no. 6, pp. 446-453, 2002.
[25]	J. Ten Hoeve, M. D. J. Ibarra-Sanchez, Y. Fu et al., “Identification of a nuclear Stat1 protein tyrosine phosphatase,” Molecular and Cellular Biology, vol. 22, no. 16, pp. 5662-5668, 2002.
[26]	M. Hallé, M. A. Gomez, M. Stuible et al., “The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38mitogen-activated protein kinase inactivation,” The Journal of Biological Chemistry, vol. 284, no. 11, pp. 6893-6908, 2009.
[27]	D. Nandan, T. Yi, M. Lopez, C. Lai, and N. E. Reiner, “Leishmania EF-1α activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation,” The Journal of Biological Chemistry, vol. 277, no. 51, pp. 50190-50197, 2002.
[28]	S. Antoniazi, H. P. Price, P. Kropf et al., “Chemokine gene expression in Toll-like receptor-competent and -deficient mice infected with Leishmania major,” Infection and Immunity, vol. 72, no. 9, pp. 5168-5174, 2004.
[29]	G. Forget, C. Matte, K. A. Siminovitch, S. Rivest, P. Pouliot, and M. Olivier, “Regulation of the Leishmania-induced innate inflammatory response by the protein tyrosine phosphatase SHP-1,” European Journal of Immunology, vol. 35, no. 6, pp. 1906–1917, 2005.
[30]	M. J. Teixeira, C. R. Teixeira, B. B. Andrade, M. Barral-Netto, and A. Barral, “Chemokines in host-parasite interactions in leishmaniasis,” Trends in Parasitology, vol. 22, no. 1, pp. 32-40, 2006.
[31]	D. Rousseau, S. Demartino, F. Anjuère et al., “Sustained parasite burden in the spleen of Leishmania infantum-infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection against challenge,” European Cytokine Network, vol. 12, no. 2, pp. 340-347, 2001.
[32]	P. Das, A. Lahiri, A. Lahiri, and D. Chakravortty, “Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator,” PLoS Pathogens, vol. 6, no. 6, Article ID e1000899, 2010.
[33]	J. Osorio y Fortéa, E. de La Llave, B. Regnault et al., “Transcriptional signatures of BALB/c mouse macrophages housing multiplying Leishmania amazonensis amastigotes,” BMC Genomics, vol. 10, article 119, 2009.
[34]	R. Lodge, T. O. Diallo, and A. Descoteaux, “Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane,” Cellular Microbiology, vol. 8, no. 12, pp. 1922-1931, 2006.
[35]	R. Lodge and A. Descoteaux, “Phagocytosis of Leishmania donovani amastigotes is Rac1 dependent and occurs in the absence of NADPH oxidase activation,” European Journal of Immunology, vol. 36, no. 10, pp. 2735-2744, 2006.
[36]	A. Fontayne, P. M. C. Dang, M. A. Gougerot-Pocidalo, and J. El Benna, “Phosphorylation of p47phox sites by PKC α, βII, δ, and ζ: effect on binding to p22phox and on NADPH oxidase activation,” Biochemistry, vol. 41, no. 24, pp. 7743-7750, 2002.
[37]	R. M. Mukbel, C. Patten, K. Gibson, M. Ghosh, C. Petersen, and D. E. Jones, “Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide,” American Journal of Tropical Medicine and Hygiene, vol. 76, no. 4, pp. 669-675, 2007.
[38]	M. Del Vecchio, E. Bajetta, S. Canova et al., “Interleukin-12: biological properties and clinical application,” Clinical Cancer Research, vol. 13, no. 16, pp. 4677-4685, 2007.
[39]	I. Abu-Dayyeh, M. T. Shio, S. Sato, S. Akira, B. Cousineau, and M. Olivier, “Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif,” PLoS Neglected Tropical Diseases, vol. 2, no. 12, article e305, 2008.
[40]	M. C. De Almeida, S. A. Cardoso, and M. Barral-Netto, “Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage,” International Journal for Parasitology, vol. 33, no. 2, pp. 153-162, 2003.
[41]	C. Ropert and R. T. Gazzinelli, “Regulatory role of toll-like receptor 2 during infection with Trypanosoma cruzi,” Journal of Endotoxin Research, vol. 10, no. 6, pp. 425-430, 2004.
[42]	A.-C. Oliveira, J. R. Peixoto, L. B. De Arrada et al., “Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi,” The Journal of Immunology, vol. 173, no. 9, pp. 5688-5696, 2004.
[43]	C. Ropert, M. Closel, A. C. L. Chaves, and R. T. Gazzinelli, “Inhibition of a p38/stress-activated protein kinase-2-dependent phosphatase restores function of IL-1 receptor-associated kinase-1 and reverses Toll-like receptor 2- and 4-dependent tolerance of macrophages,” The Journal of Immunology, vol. 171, no. 3, pp. 1456-1465, 2003.
[44]	M. J. de Veer, J. M. Curtis, T. M. Baldwin et al., “MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling,” European Journal of Immunology, vol. 33, no. 10, pp. 2822-2831, 2003.
[45]	I. Becker, N. Salaiza, M. Aguirre et al., “Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2,” Molecular and Biochemical Parasitology, vol. 130, no. 2, pp. 65-74, 2003.
[46]	J. F. Flandin, F. Chano, and A. Descoteaux, “RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-γ-primed macrophages,” European Journal of Immunology, vol. 36, no. 2, pp. 411-420, 2006.
[47]	F. Debierre-Grockiego, M. A. Campos, N. Azzouz et al., “Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii,” The Journal of Immunology, vol. 179, no. 2, pp. 1129-1137, 2007.